Safety and efficacy of mirabegron as ‘add‐on’ therapy in patients with overactive bladder treated with solifenacin: a post‐marketing, open‐label study in Japan (MILAI study)
暂无分享，去创建一个
Y. Homma | H. Kakizaki | O. Yamaguchi | N. Seki | M. Takeda | O. Yokoyama | M. Gotoh | Y. Igawa | O. Nishizawa | Masaki Yoshida | Kentarou Kuroishi | Akira Okitsu | Takuya Hamada | Akiko Kobayashi